Similar articles

• Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.

  Kotapati S. Kotapati S. Conn Med. 2002 May;66(5):269-72. Conn Med. 2002. PMID: 12071108 Review. No abstract available.
• Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.

  Kim CH, Park SH, Sim YB, Kim SS, Kim SJ, Lim SM, Jung JS, Suh HW. Kim CH, et al. Brain Res Bull. 2014 May;104:36-41. doi: 10.1016/j.brainresbull.2014.02.003. Epub 2014 Apr 2. Brain Res Bull. 2014. PMID: 24704461
• A new crystal form of nateglinide.

  Li G, Su GQ, Xu QW, Zhu CQ. Li G, et al. Yao Xue Xue Bao. 2001 Jul;36(7):532-4. Yao Xue Xue Bao. 2001. PMID: 12585087
• Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.

  Iwase M, Iino K, Doi Y, Asano T, Iida M. Iwase M, et al. Diabetes Res Clin Pract. 2008 Dec;82(3):e19-22. doi: 10.1016/j.diabres.2008.09.001. Epub 2008 Oct 11. Diabetes Res Clin Pract. 2008. PMID: 18849086 Clinical Trial.
• Nateglinide: A comprehensive profile.

  Alanazi MM. Alanazi MM. Profiles Drug Subst Excip Relat Methodol. 2025;50:43-96. doi: 10.1016/bs.podrm.2024.10.002. Epub 2025 Jan 9. Profiles Drug Subst Excip Relat Methodol. 2025. PMID: 39855778 Review.